Q-Line Biotech IPO GMP Day 1 21 May 2026: Rs 110 Peak Grey Market Premium Signals 32% Listing Gain as Subscription Opens

May 21, 2026
Posted by: Ankit Jaiswal
Category: IPO

The Q-Line Biotech IPO opened for subscription today, 21 May 2026 (Day 1), on the NSE SME platform. The grey market premium has been the headline: IPOWatch recorded a high of Rs 110 on 20 May 2026, implying an expected listing price of Rs 453 (a 32.07 percent premium over the Rs 343 upper band). The steadier IPOGuru reading stands at Rs 42 (12.25 percent premium, expected listing Rs 385). Day 1 subscription data is at 0x in opening hours, entirely normal for the first few hours of an NSE SME issue. The IPO closes on 25 May 2026 and lists on 29 May 2026.

Table of Contents

Q-Line Biotech IPO Day 1 Key Data

Day 1 Date: 21 May 2026 (Today)
Close Date: 25 May 2026 (Sunday)
Allotment: 26 May 2026
Listing: 29 May 2026 on NSE SME
Price Band: Rs 326 to Rs 343 per share
Issue Size: Rs 214 crore (62.53 lakh shares, 100% fresh issue)
Lot Size: 400 shares | Minimum Retail: 800 shares = Rs 2,74,400
Day 1 Subscription: 0x (opening hours, data building)
GMP High (IPOWatch, 20 May): Rs 110, implied listing Rs 453 (+32.07%)
GMP Steady (IPOGuru): Rs 42, implied listing Rs 385 (+12.25%)
Category split: QIB 50%, NII 15%, Retail 35%

Tap to Access Best Research Pieces on Univest

The Rs 110 GMP: What It Means

The Q-Line Biotech IPO GMP divergence between IPOWatch (Rs 110, peak on 20 May) and IPOGuru (Rs 42, steady) is the most important data point on Day 1. The Rs 110 peak suggests some grey market buyers are aggressively pricing in strong subscription data and the diagnostic sector tailwind. However, IPOGuru’s Rs 42 steady reading represents a more conservative and likely more accurate grey market consensus. For Day 1 investors, Rs 42 to Rs 65 is the realistic GMP range to use for expected listing price estimates. At Rs 42: implied listing Rs 385 (12.25% premium). At Rs 65: implied listing Rs 408 (18.95% premium).

GMP is unofficial and volatile. The Day 3 subscription data (25 May) will be the most reliable signal before listing. QIBs (50% of the issue) rarely subscribe on Day 1 and will drive the final subscription number on Days 2 and 3. Monitor QIB data closely.

Track live Q-Line Biotech IPO subscription on the Check the Univest Screener for live data.

About Q-Line Biotech

Surat-based IVD (In-Vitro Diagnostic) products manufacturer with 15-plus years in diagnostics. Manufactures diagnostic reagents, rapid test kits, pathology instruments and indigenous analysers (Selectra Pro M, Q-Count 5). Serves 150-plus national and international clients. FY25 revenue Rs 322.58 crore (+56.3% YoY). FY25 PAT Rs 28.13 crore (DECLINED from Rs 34.44 crore in FY24 despite revenue doubling — key risk). Use of proceeds: Rs 110 crore working capital + Rs 90 crore debt repayment.

Disclaimer: Investment in the share market is subject to risk. This article is for informational and educational purposes only and does not constitute investment advice. Verify all numbers before investing. Consult a SEBI-registered advisor before making investment decisions.

Download the Univest iOS App or the Univest Android App to get daily stock recommendations and insightful research pieces on Q-Line Biotech IPO live subscription and GMP tracker on Univest!

FAQs

What is the Q-Line Biotech IPO GMP on Day 1?

Ans. The Q-Line Biotech IPO GMP on Day 1 (21 May 2026) peaked at Rs 110 per IPOWatch on 20 May (implied listing Rs 453, +32.07%) while IPOGuru shows a steady Rs 42 (implied Rs 385, +12.25%). The Rs 42 reading is the more conservative estimate. GMP is unofficial.

What is the Q-Line Biotech IPO minimum investment?

Ans. The minimum retail application is 2 lots of 400 shares each (800 shares) at the Rs 343 upper band, requiring Rs 2,74,400. The issue closes 25 May and lists 29 May on NSE SME.

IPO GMP Day 1

Author: Ankit Jaiswal

Ankit Jaiswal is the Senior Research Analyst at Univest, leading the platform's in-house equity research desk and serving as the editorial reviewer for all research and blog content published at univest.in. With 11+ years of experience in Indian equity markets, he oversees stock recommendations, earnings analysis, sector coverage, and ensures every published article meets SEBI Research Analyst Regulations. He holds a Bachelor of Commerce (B.Com) from St. Xavier's College, Kolkata — one of India's most prestigious commerce institutions — and has cleared CMT Level 2 from the CMT Association, a globally recognised certification in technical analysis and market research. His research methodology combines fundamental analysis (earnings quality, balance sheet strength, management commentary) with advanced technical analysis (chart patterns, momentum indicators, market structure) — giving Univest's retail investors a dual-lens approach that most Indian research platforms lack. Ankit is among the most comprehensively certified analysts in Indian financial media, holding five NISM certifications: Series-XV (Research Analyst), Series-VIII (Equity Derivatives), Series-VII (SORM), Series-VI (Depository Operations), and Series-V-A (Mutual Fund Distributors). At Univest — India's SEBI-registered research and advisory platform — Ankit's responsibilities include leading the research team, finalising stock recommendations published across Pro Lite, Pro Super, and Pro Gold advisory services, and maintaining editorial oversight of all YMYL financial content published on the blog.